TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile Sells 5,000 Shares

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) Director Edward M. Basile sold 5,000 shares of TransMedics Group stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the transaction, the director now owns 2,866 shares in the company, valued at approximately $362,405.70. This trade represents a 63.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX traded up $4.80 during midday trading on Tuesday, reaching $128.74. 893,951 shares of the company's stock were exchanged, compared to its average volume of 1,357,796. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market capitalization of $4.35 billion, a PE ratio of 136.96 and a beta of 1.91. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company's 50 day simple moving average is $96.37 and its two-hundred day simple moving average is $78.80.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. During the same quarter in the previous year, the company posted $0.35 EPS. The business's revenue for the quarter was up 48.2% compared to the same quarter last year. Equities research analysts expect that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Clear Creek Financial Management LLC bought a new stake in TransMedics Group in the fourth quarter valued at about $352,000. Vaughan Nelson Investment Management L.P. increased its stake in TransMedics Group by 9.9% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 361,615 shares of the company's stock valued at $22,547,000 after purchasing an additional 32,605 shares in the last quarter. Baillie Gifford & Co. increased its stake in TransMedics Group by 14.9% in the fourth quarter. Baillie Gifford & Co. now owns 269,836 shares of the company's stock valued at $16,824,000 after purchasing an additional 34,947 shares in the last quarter. State of Michigan Retirement System bought a new stake in TransMedics Group in the fourth quarter valued at approximately $6,734,000. Finally, Peregrine Capital Management LLC increased its stake in TransMedics Group by 64.0% in the fourth quarter. Peregrine Capital Management LLC now owns 66,140 shares of the company's stock valued at $4,124,000 after purchasing an additional 25,814 shares in the last quarter. Institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Tuesday. Piper Sandler restated an "overweight" rating and issued a $125.00 target price (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Oppenheimer boosted their price target on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Canaccord Genuity Group reissued a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a research report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, TransMedics Group has a consensus rating of "Moderate Buy" and an average target price of $126.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.